Judah Frommer – Morgan Stanley

Morgan Stanley

A Morgan Stanley analyst with 9 tracked ratings across 9 distinct tickers has a 1.6 out of 5 stars track record, predominantly issuing 6 bullish and 3 hold ratings as of May 8, 2026.

Aggregated from multiple market-data sources

Total ratings

Tickers covered

Sources

Aggregated

Latest rating

21 days ago

2026-05-14 00:00:00+00

Track record

Aggregated

No track record data

Bullish: 11
Hold: 5
Bearish: 0

Aggregated

22% success rate

Bullish: 0
Hold: 2
Bearish: 0

Aggregated

Not available

Bullish: 20
Hold: 0
Bearish: 3

Recent ratings

Ticker	Date	Rating	Price target	Source
CMPS	2026-05-14	buy	$17.00	Aggregated
ZBIO	2026-05-14	unknown	$22.00	Aggregated
BCAX	2026-05-12	buy	$37.00	Aggregated
EVMN	2026-05-11	buy	$55.00	Aggregated
GMAB	2026-05-08	hold	$33.00	Aggregated
PTCT	2026-05-08	buy	$94.00	Aggregated
ARQT	2026-05-07	buy	$34.00	Aggregated
ENGN	2026-05-07	hold	-	Aggregated
TRVI	2026-05-05	buy	$20.00	Aggregated
KYMR	2026-05-01	buy	$119.00	Aggregated
KLRS	2026-04-16	buy	$14.00	Aggregated
APLS	2026-03-31	hold	$41.00	Aggregated
IMMX	2026-03-25	buy	$20.00	Aggregated
FDMT	2026-03-18	hold	-	Aggregated
TRVI	2026-03-18	buy	$18.00	Aggregated
ZBIO	2026-03-17	unknown	$21.00	Aggregated
RGNX	2026-03-06	buy	$17.00	Aggregated
AGMB	2026-03-03	buy	$28.00	Aggregated
BLTE	2026-03-03	buy	$201.00	Aggregated
CLDX	2026-02-26	buy	$44.00	Aggregated
GMAB	2026-02-16	unknown	$34.00	Aggregated
INCY	2026-02-11	hold	$102.00	Aggregated
RGNX	2026-02-10	buy	$18.00	Aggregated
ABVX	2026-01-09	buy	$145.00	Aggregated
BLTE	2026-01-06	buy	$191.00	Aggregated
EVMN	2025-12-01	buy	$36.00	Aggregated
TRVI	2025-11-14	buy	$19.00	Aggregated
ZBIOZENAS BIOPHARMA, INC. COMMON STOCK	2025-11-13	unknown	$37.00	Aggregated
ABVX	2025-09-12	buy	$101.00	Aggregated
ABVXABIVAX - ADR	2025-09-12	unknown	$101.00	Aggregated
TRVI	2025-08-21	buy	$18.00	Aggregated
APLS	2025-07-02	unknown	$26.00	Aggregated
APLSAPELLIS PHARMACEUTICALS INC	2025-07-02	unknown	$26.00	Aggregated
BPMCBLUEPRINT MEDICINES CORP	2025-06-05	hold	$129.00	Aggregated
CLDX	2025-05-09	buy	$43.00	Aggregated
ABVX	2025-03-20	unknown	$12.00	Aggregated
CLDX	2025-03-20	buy	$46.00	Aggregated
RGNX	2025-03-14	buy	$24.00	Aggregated
GLPG	2025-02-14	sell	$22.00	Aggregated
GLPGGALAPAGOS NV - ADR	2025-02-14	unknown	$22.00	Aggregated
FDMT	2025-01-13	sell	$6.00	Aggregated
APLS	2024-11-21	unknown	$31.00	Aggregated
FDMT	2024-11-21	sell	$8.00	Aggregated
FDMT4D MOLECULAR THERAPEUTICS INC	2024-11-21	hold	$8.00	Aggregated
ACLXARCELLX INC	2024-11-06	unknown	$106.00	Aggregated
BCAX	2024-10-08	buy	$35.00	Aggregated
BCAXBICARA THERAPEUTICS INC. COMMON STOCK	2024-10-08	unknown	$35.00	Aggregated
GLPG	2024-04-22	unknown	$38.00	Aggregated
MURAMURAL ONCOLOGY PLC	2024-04-04	unknown	$13.00	Aggregated
GLPG	2024-03-07	unknown	$38.00	Aggregated

Tickers covered(31)

Ticker	Ratings	Last rating	Sources
CMPS	2	2026-05-14	Aggregated
ZBIO	2	2026-05-14	Aggregated
BCAX	4	2026-05-12	Aggregated
EVMN	2	2026-05-11	Aggregated
GMAB	2	2026-05-08	Aggregated
PTCT	2	2026-05-08	Aggregated
ARQT	1	2026-05-07	Aggregated
ENGN	1	2026-05-07	Aggregated
TRVI	4	2026-05-05	Aggregated
KYMR	1	2026-05-01	Aggregated
KLRS	1	2026-04-16	Aggregated
APLS	3	2026-03-31	Aggregated
IMMX	1	2026-03-25	Aggregated
FDMT	3	2026-03-18	Aggregated
RGNX	3	2026-03-06	Aggregated
AGMB	1	2026-03-03	Aggregated
BLTE	3	2026-03-03	Aggregated
CLDX	3	2026-02-26	Aggregated
INCY	1	2026-02-11	Aggregated
ABVX	4	2026-01-09	Aggregated
ZBIOZENAS BIOPHARMA, INC. COMMON STOCK	1	2025-11-13	Aggregated
ABVXABIVAX - ADR	1	2025-09-12	Aggregated
APLSAPELLIS PHARMACEUTICALS INC	1	2025-07-02	Aggregated
BPMCBLUEPRINT MEDICINES CORP	1	2025-06-05	Aggregated
GLPG	3	2025-02-14	Aggregated
GLPGGALAPAGOS NV - ADR	1	2025-02-14	Aggregated
FDMT4D MOLECULAR THERAPEUTICS INC	1	2024-11-21	Aggregated
ACLXARCELLX INC	1	2024-11-06	Aggregated
BCAXBICARA THERAPEUTICS INC. COMMON STOCK	1	2024-10-08	Aggregated
MURAMURAL ONCOLOGY PLC	1	2024-04-04	Aggregated
PROK	1	2024-03-07	Aggregated

Methodology differs by source. Track records are aggregated from multiple sources; scoring methodology and scales differ by source and values are not directly comparable. Coverage is sourced from publicly-aggregated analyst activity. Past performance does not guarantee future results. Not investment advice.